Anti-allergic properties of a new all-D synthetic immunoglobulin-binding peptide (431 views)
Mol Immunol (ISSN: 0161-5890), 2008 Jan; 45(1): 226-234.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.555, 5-year impact factor: 3.583
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-34548305099&partnerID=40&md5=bbbcbbec674f0b3d7ccd524ecba53032
Keywords: Active Cutaneous Anaphylaxis, Allergic Disorders, Passive Cutaneous Anaphylaxis, Antiallergic Agent, Beta N Acetylhexosaminidase, Binding Protein, Immunoglobulin E, Ketotifen, Tg 19320, Tg19318, Unclassified Drug, Animal Cell, Animal Experiment, Animal Model, Article, Atopy, Controlled Study, Drug Dose Increase, Enzyme Linked Immunosorbent Assay, Female, Mast Cell Degranulation, Mouse, Nonhuman, Passive Skin Anaphylaxis, Priority Journal, Protein Analysis, Protein Binding, Protein Determination, Protein Variant, Surface Plasmon Resonance, 4-Dinitrophenol, Anti-Allergic Agents, Biotinylation, Peptides, Protein Conformation, Rattus,
Affiliations:
*** IBB - CNR ***
Tecnogen S.p.A., Localita La Fagianeria, 81015 Piana di Monte Verna, CE, Italy
Tecnogen S. p. A., Localita La Fagianeria, 81015 Piana di Monte Verna, CE, Italy
References:
Adkinson, N.F., Eggleston, P.A., Eney, D., Goldstain, E.O., Schuberth, K.C., Bacon, J.R., Hamilton, R.G., Wheeler, B., A controlled trial of immunotherapy for asthma in allergic children (1997) N. Engl. J. Med., 336, pp. 324-33
Alter, B.P., Gaston, T., Lipton, J.M., Lack of effect of corticosteroids in W/Wv and S1/S1d mice: these strains are not a model for steroid-responsive Diamond-Blackfan anemia (1993) Eur. J. Haematol., 50, pp. 275-278
Barnes, P.J., Pedersen, S., Busse, W.W., Efficacy and safety of inhaled corticosteroids: an update (1998) Am. J. Respir. Crit. Care Med., 157, pp. S1-S53
Barnes, P.J., Therapeutic strategies for allergic diseases (1999) Nature, 402 (SUPPL), pp. B31-B38
Baylink, D.J., Glucocorticoid-induced osteoporosis (1983) N. Engl. J. Med., 309, pp. 306-308
Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Della Cioppa, G., The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma (2005) Allergy, 60, pp. 302-308
Buku, A., Condie, B.A., Price, J.A., Mezei, M., [Ala12]MCD peptide: a lead peptide to inhibitors of immunoglobulin E binding to mast cell receptors (2005) J. Pept. Res., 66, pp. 132-137
Fassina, G., Verdoliva, A., Odierna, M.R., Ruvo, M., Cassani, G., Protein A mimetic peptide ligand for affinity purification of antibodies (1996) J. Mol. Recognit., 9, pp. 564-569
Hoffmann, A., Jamin, A., Foetisch, K., May, S., Aulepp, H., Haustein, D., Vieths, S., Determination of the allergenic activity of birch pollen and apple prick test solutions by measurement of β-hexosaminidase release from RBL 2H3 cells. Comparison with classical methods in allergen standardization (1999) Allergy, 54, pp. 446-454
Inagaki, N., Goro, S., Nagai, H., Koda, A., Pharmacological characterization of mouse ear PCA (1985) Int. Arch. Allergy Appl. Immunol., 78, pp. 113-117
Inagaki, N., Miura, T., Nagai, H., Koda, A., Active cutaneous anaphylaxis (ACA) in the mouse ear (1992) Jpn. J. Pharmacol., 59, pp. 201-208
Inagaki, N., Nagai, H., Drugs for the treatment of allergic diseases (2001) Jpn. J. Pharmacol., 86, pp. 275-280
Joly, F., Bessou, G., Benveniste, J., Ninio, E., Ketotifen inhibits paf-acether biosynthesis and beta-hexosaminidase release in mouse mast cells stimulated with antigen (1987) Eur. J. Pharma., 144, pp. 133-139
Kinet, J.P., Blank, U., Brini, A., Jouvin, M.H., Kuster, H., Mejan, O., Ra, C., The high-affinity receptor for immunoglobulin E: a target for therapy of allergic diseases (1991) Int. Arch. Allergy Appl. Immunol., 94, pp. 51-55
Lee, E., Choi, E.J., Cheong, H., Kim, Y.-R., Ryu, S.Y., Kim, K.-M., Anti-allergic actions of the leaves of Castanea crenata and isolation of an active component responsible for the inhibition of mast cell degranulation (1999) Arch. Pharm. Res., 22, pp. 320-323
Marino, M., Ruvo, M., De Falco, S., Fassina, G., Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide (2000) Nat. Biotechnol., 18, pp. 735-739
Marino, M., Rossi, M., Ruvo, M., Fassina, G., Novel molecular targets for systemic lupus erythematosus (2002) Curr. Drug Targets, 3, pp. 223-228
Marshall, G.D., Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents (2000) J. Allergy Clin. Immunol., 106, pp. 303-309
Meltzer, E.O., Grant, J.A., Impact of ceterizine on the burden of allergic rhinitis (1999) Ann. Allergy Asthma Immunol., 83, pp. 455-463
Michaelsen, T.E., Ihle, Ø., Beckstrøm, K.J., Herstad, T.K., Kolberg, J., Høiby, E.A., Aase, A., Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes (2003) Infect. Immun., 71, pp. 5714-5723
Nakamura, G.R., Starovasnik, A., Reynolds, M.E., Lowman, H.B., A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor (2001) Biochemistry, 40, pp. 9828-9835
Nakamura, G.R., Reynolds, M.E., Chen, Y.M., Starovasnik, M.A., Lowman, H.B., Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor (2002) Proc. Natl. Acad. Sci. U.S.A., 99, pp. 1303-1308
Ovary, Z., Immediate reactions in the skin of experimental animals provoked by antibody-antigen interaction (1958) Prog. Allergy, 5, pp. 459-508
Palombo, G., Rossi, M., Cassani, G., Fassina, G., Affinity purification of mouse monoclonal IgE using a protein A mimetic ligand (TG19318) immobilized on solid supports (1998) J. Mol. Recognit., 11, pp. 247-249
Palombo, G., De Falco, S., Tortora, M., Cassani, G., Fassina, G., A synthetic ligand for IgA affinity purification (1998) J. Mol. Recognit., 11, pp. 243-246
Palombo, G., Verdoliva, A., Fassina, G., Affinity purification of immunoglobulin M using a novel synthetic ligand (1998) J. Chromatogr. B Biomed. Sci. Appl., 715, pp. 137-145
Piper, J.M., Ray, W.A., Daugherty, J.R., Griffin, M.R., Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs (1991) Ann. Intern. Med., 114, pp. 735-740
Presta, L.G., Lahr, S.J., Shields, R.L., Porter, J.P., Gorman, C.M., Fendly, B.M., Jardieu, P.M., Humanization of an antibody direct against IgE (1993) J. Immunol., 151, pp. 2623-2632
Rigby, L.J., Trist, H., Snider, J., Hulett, M.D., Hogarth, P.M., Monoclonal antibodies and synthetic peptides define the active site of FcepsilonRI and a potential receptor antagonist (2000) Allergy, 55, pp. 609-619
Russo, A., Russo, G., Peticca, M., Pietropaolo, C., Di Rosa, M., Iuvone, T., Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5 (2005) Br. J. Pharmacol., 145, pp. 24-33
Till, S.J., Francis, J.N., Nouri-Aria, K., Durham, S.R., Mechanisms of immunotherapy (2004) J. Allergy Clin. Immunol., 113, pp. 1025-1034
van der Kleij, H.P., Kraneveld, A., van Houwelingen, A.H., Kool, M., Weitemberg, A.C., Redegeld, F.A., Nijkamp, F.P., Murine model for non-IgE-mediated asthma (2004) Inflammation, 28, pp. 115-125
Verdoliva, A., Basile, G., Fassina, G., Affinity purification of immunoglobulins from chicken egg yolk using a new synthetic ligand (2000) J. Chromatogr. B, 749, pp. 233-242
Verdoliva, A., Pannone, F., Rossi, M., Catello, S., Manfredi, V., Affinity purification of polyclonal antibodies using a new all-D synthetic peptide ligand: comparison with protein A and protein G (2002) J. Immunol. Methods, 271, pp. 77-88
Wiegand, T.W., Williams, P.B., Dreskin, S.C., Jouvin, M.H., Kinet, J.P., Tasset, D., High-affinity oligonucleotide ligands to human IgE Inhibit binding to Fcε Receptor I (1996) J. Immunol., 157, pp. 221-230
Yamanishi, R., Kondo, K., Tsuji, H., Ogawa, T., Micro-assay to Measure the allergenicity of Kunitz-type Soybean Trypsin Inhibitor toward Balb/c Mice by Using RBL-2H3 Cells (1995) Biosci. Biotech. Biochem., 59, pp. 1272-1275
Yan, H., Lamm, M.E., Björling, E., Huang, Y.T., Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model (2002) J. Virol., 76, pp. 10972-10979
Adkinson, N. F., Eggleston, P. A., Eney, D., Goldstain, E. O., Schuberth, K. C., Bacon, J. R., Hamilton, R. G., Wheeler, B., A controlled trial of immunotherapy for asthma in allergic children (1997) N. Engl. J. Med., 336, pp. 324-33
Alter, B. P., Gaston, T., Lipton, J. M., Lack of effect of corticosteroids in W/Wv and S1/S1d mice: these strains are not a model for steroid-responsive Diamond-Blackfan anemia (1993) Eur. J. Haematol., 50, pp. 275-278
Barnes, P. J., Pedersen, S., Busse, W. W., Efficacy and safety of inhaled corticosteroids: an update (1998) Am. J. Respir. Crit. Care Med., 157, pp. S1-S53
Barnes, P. J., Therapeutic strategies for allergic diseases (1999) Nature, 402 (SUPPL), pp. B31-B38
Baylink, D. J., Glucocorticoid-induced osteoporosis (1983) N. Engl. J. Med., 309, pp. 306-308
Kinet, J. P., Blank, U., Brini, A., Jouvin, M. H., Kuster, H., Mejan, O., Ra, C., The high-affinity receptor for immunoglobulin E: a target for therapy of allergic diseases (1991) Int. Arch. Allergy Appl. Immunol., 94, pp. 51-55
Lee, E., Choi, E. J., Cheong, H., Kim, Y. -R., Ryu, S. Y., Kim, K. -M., Anti-allergic actions of the leaves of Castanea crenata and isolation of an active component responsible for the inhibition of mast cell degranulation (1999) Arch. Pharm. Res., 22, pp. 320-323
Marshall, G. D., Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents (2000) J. Allergy Clin. Immunol., 106, pp. 303-309
Meltzer, E. O., Grant, J. A., Impact of ceterizine on the burden of allergic rhinitis (1999) Ann. Allergy Asthma Immunol., 83, pp. 455-463
Michaelsen, T. E., Ihle, ., Beckstr m, K. J., Herstad, T. K., Kolberg, J., H iby, E. A., Aase, A., Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1. 7 and P1. 16 epitopes (2003) Infect. Immun., 71, pp. 5714-5723
Nakamura, G. R., Starovasnik, A., Reynolds, M. E., Lowman, H. B., A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor (2001) Biochemistry, 40, pp. 9828-9835
Nakamura, G. R., Reynolds, M. E., Chen, Y. M., Starovasnik, M. A., Lowman, H. B., Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor (2002) Proc. Natl. Acad. Sci. U. S. A., 99, pp. 1303-1308
Piper, J. M., Ray, W. A., Daugherty, J. R., Griffin, M. R., Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs (1991) Ann. Intern. Med., 114, pp. 735-740
Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., Jardieu, P. M., Humanization of an antibody direct against IgE (1993) J. Immunol., 151, pp. 2623-2632
Rigby, L. J., Trist, H., Snider, J., Hulett, M. D., Hogarth, P. M., Monoclonal antibodies and synthetic peptides define the active site of FcepsilonRI and a potential receptor antagonist (2000) Allergy, 55, pp. 609-619
Till, S. J., Francis, J. N., Nouri-Aria, K., Durham, S. R., Mechanisms of immunotherapy (2004) J. Allergy Clin. Immunol., 113, pp. 1025-1034
van der Kleij, H. P., Kraneveld, A., van Houwelingen, A. H., Kool, M., Weitemberg, A. C., Redegeld, F. A., Nijkamp, F. P., Murine model for non-IgE-mediated asthma (2004) Inflammation, 28, pp. 115-125
Wiegand, T. W., Williams, P. B., Dreskin, S. C., Jouvin, M. H., Kinet, J. P., Tasset, D., High-affinity oligonucleotide ligands to human IgE Inhibit binding to Fc Receptor I (1996) J. Immunol., 157, pp. 221-230
Yan, H., Lamm, M. E., Bj rling, E., Huang, Y. T., Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model (2002) J. Virol., 76, pp. 10972-10979
Mol Immunol (ISSN: 0161-5890), 2008 Jan; 45(1): 226-234.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.555, 5-year impact factor: 3.583
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-34548305099&partnerID=40&md5=bbbcbbec674f0b3d7ccd524ecba53032
Keywords: Active Cutaneous Anaphylaxis, Allergic Disorders, Passive Cutaneous Anaphylaxis, Antiallergic Agent, Beta N Acetylhexosaminidase, Binding Protein, Immunoglobulin E, Ketotifen, Tg 19320, Tg19318, Unclassified Drug, Animal Cell, Animal Experiment, Animal Model, Article, Atopy, Controlled Study, Drug Dose Increase, Enzyme Linked Immunosorbent Assay, Female, Mast Cell Degranulation, Mouse, Nonhuman, Passive Skin Anaphylaxis, Priority Journal, Protein Analysis, Protein Binding, Protein Determination, Protein Variant, Surface Plasmon Resonance, 4-Dinitrophenol, Anti-Allergic Agents, Biotinylation, Peptides, Protein Conformation, Rattus,
Affiliations:
*** IBB - CNR ***
Tecnogen S.p.A., Localita La Fagianeria, 81015 Piana di Monte Verna, CE, Italy
Tecnogen S. p. A., Localita La Fagianeria, 81015 Piana di Monte Verna, CE, Italy
References:
Adkinson, N.F., Eggleston, P.A., Eney, D., Goldstain, E.O., Schuberth, K.C., Bacon, J.R., Hamilton, R.G., Wheeler, B., A controlled trial of immunotherapy for asthma in allergic children (1997) N. Engl. J. Med., 336, pp. 324-33
Alter, B.P., Gaston, T., Lipton, J.M., Lack of effect of corticosteroids in W/Wv and S1/S1d mice: these strains are not a model for steroid-responsive Diamond-Blackfan anemia (1993) Eur. J. Haematol., 50, pp. 275-278
Barnes, P.J., Pedersen, S., Busse, W.W., Efficacy and safety of inhaled corticosteroids: an update (1998) Am. J. Respir. Crit. Care Med., 157, pp. S1-S53
Barnes, P.J., Therapeutic strategies for allergic diseases (1999) Nature, 402 (SUPPL), pp. B31-B38
Baylink, D.J., Glucocorticoid-induced osteoporosis (1983) N. Engl. J. Med., 309, pp. 306-308
Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Della Cioppa, G., The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma (2005) Allergy, 60, pp. 302-308
Buku, A., Condie, B.A., Price, J.A., Mezei, M., [Ala12]MCD peptide: a lead peptide to inhibitors of immunoglobulin E binding to mast cell receptors (2005) J. Pept. Res., 66, pp. 132-137
Fassina, G., Verdoliva, A., Odierna, M.R., Ruvo, M., Cassani, G., Protein A mimetic peptide ligand for affinity purification of antibodies (1996) J. Mol. Recognit., 9, pp. 564-569
Hoffmann, A., Jamin, A., Foetisch, K., May, S., Aulepp, H., Haustein, D., Vieths, S., Determination of the allergenic activity of birch pollen and apple prick test solutions by measurement of β-hexosaminidase release from RBL 2H3 cells. Comparison with classical methods in allergen standardization (1999) Allergy, 54, pp. 446-454
Inagaki, N., Goro, S., Nagai, H., Koda, A., Pharmacological characterization of mouse ear PCA (1985) Int. Arch. Allergy Appl. Immunol., 78, pp. 113-117
Inagaki, N., Miura, T., Nagai, H., Koda, A., Active cutaneous anaphylaxis (ACA) in the mouse ear (1992) Jpn. J. Pharmacol., 59, pp. 201-208
Inagaki, N., Nagai, H., Drugs for the treatment of allergic diseases (2001) Jpn. J. Pharmacol., 86, pp. 275-280
Joly, F., Bessou, G., Benveniste, J., Ninio, E., Ketotifen inhibits paf-acether biosynthesis and beta-hexosaminidase release in mouse mast cells stimulated with antigen (1987) Eur. J. Pharma., 144, pp. 133-139
Kinet, J.P., Blank, U., Brini, A., Jouvin, M.H., Kuster, H., Mejan, O., Ra, C., The high-affinity receptor for immunoglobulin E: a target for therapy of allergic diseases (1991) Int. Arch. Allergy Appl. Immunol., 94, pp. 51-55
Lee, E., Choi, E.J., Cheong, H., Kim, Y.-R., Ryu, S.Y., Kim, K.-M., Anti-allergic actions of the leaves of Castanea crenata and isolation of an active component responsible for the inhibition of mast cell degranulation (1999) Arch. Pharm. Res., 22, pp. 320-323
Marino, M., Ruvo, M., De Falco, S., Fassina, G., Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide (2000) Nat. Biotechnol., 18, pp. 735-739
Marino, M., Rossi, M., Ruvo, M., Fassina, G., Novel molecular targets for systemic lupus erythematosus (2002) Curr. Drug Targets, 3, pp. 223-228
Marshall, G.D., Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents (2000) J. Allergy Clin. Immunol., 106, pp. 303-309
Meltzer, E.O., Grant, J.A., Impact of ceterizine on the burden of allergic rhinitis (1999) Ann. Allergy Asthma Immunol., 83, pp. 455-463
Michaelsen, T.E., Ihle, Ø., Beckstrøm, K.J., Herstad, T.K., Kolberg, J., Høiby, E.A., Aase, A., Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes (2003) Infect. Immun., 71, pp. 5714-5723
Nakamura, G.R., Starovasnik, A., Reynolds, M.E., Lowman, H.B., A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor (2001) Biochemistry, 40, pp. 9828-9835
Nakamura, G.R., Reynolds, M.E., Chen, Y.M., Starovasnik, M.A., Lowman, H.B., Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor (2002) Proc. Natl. Acad. Sci. U.S.A., 99, pp. 1303-1308
Ovary, Z., Immediate reactions in the skin of experimental animals provoked by antibody-antigen interaction (1958) Prog. Allergy, 5, pp. 459-508
Palombo, G., Rossi, M., Cassani, G., Fassina, G., Affinity purification of mouse monoclonal IgE using a protein A mimetic ligand (TG19318) immobilized on solid supports (1998) J. Mol. Recognit., 11, pp. 247-249
Palombo, G., De Falco, S., Tortora, M., Cassani, G., Fassina, G., A synthetic ligand for IgA affinity purification (1998) J. Mol. Recognit., 11, pp. 243-246
Palombo, G., Verdoliva, A., Fassina, G., Affinity purification of immunoglobulin M using a novel synthetic ligand (1998) J. Chromatogr. B Biomed. Sci. Appl., 715, pp. 137-145
Piper, J.M., Ray, W.A., Daugherty, J.R., Griffin, M.R., Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs (1991) Ann. Intern. Med., 114, pp. 735-740
Presta, L.G., Lahr, S.J., Shields, R.L., Porter, J.P., Gorman, C.M., Fendly, B.M., Jardieu, P.M., Humanization of an antibody direct against IgE (1993) J. Immunol., 151, pp. 2623-2632
Rigby, L.J., Trist, H., Snider, J., Hulett, M.D., Hogarth, P.M., Monoclonal antibodies and synthetic peptides define the active site of FcepsilonRI and a potential receptor antagonist (2000) Allergy, 55, pp. 609-619
Russo, A., Russo, G., Peticca, M., Pietropaolo, C., Di Rosa, M., Iuvone, T., Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5 (2005) Br. J. Pharmacol., 145, pp. 24-33
Till, S.J., Francis, J.N., Nouri-Aria, K., Durham, S.R., Mechanisms of immunotherapy (2004) J. Allergy Clin. Immunol., 113, pp. 1025-1034
van der Kleij, H.P., Kraneveld, A., van Houwelingen, A.H., Kool, M., Weitemberg, A.C., Redegeld, F.A., Nijkamp, F.P., Murine model for non-IgE-mediated asthma (2004) Inflammation, 28, pp. 115-125
Verdoliva, A., Basile, G., Fassina, G., Affinity purification of immunoglobulins from chicken egg yolk using a new synthetic ligand (2000) J. Chromatogr. B, 749, pp. 233-242
Verdoliva, A., Pannone, F., Rossi, M., Catello, S., Manfredi, V., Affinity purification of polyclonal antibodies using a new all-D synthetic peptide ligand: comparison with protein A and protein G (2002) J. Immunol. Methods, 271, pp. 77-88
Wiegand, T.W., Williams, P.B., Dreskin, S.C., Jouvin, M.H., Kinet, J.P., Tasset, D., High-affinity oligonucleotide ligands to human IgE Inhibit binding to Fcε Receptor I (1996) J. Immunol., 157, pp. 221-230
Yamanishi, R., Kondo, K., Tsuji, H., Ogawa, T., Micro-assay to Measure the allergenicity of Kunitz-type Soybean Trypsin Inhibitor toward Balb/c Mice by Using RBL-2H3 Cells (1995) Biosci. Biotech. Biochem., 59, pp. 1272-1275
Yan, H., Lamm, M.E., Björling, E., Huang, Y.T., Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model (2002) J. Virol., 76, pp. 10972-10979
Adkinson, N. F., Eggleston, P. A., Eney, D., Goldstain, E. O., Schuberth, K. C., Bacon, J. R., Hamilton, R. G., Wheeler, B., A controlled trial of immunotherapy for asthma in allergic children (1997) N. Engl. J. Med., 336, pp. 324-33
Alter, B. P., Gaston, T., Lipton, J. M., Lack of effect of corticosteroids in W/Wv and S1/S1d mice: these strains are not a model for steroid-responsive Diamond-Blackfan anemia (1993) Eur. J. Haematol., 50, pp. 275-278
Barnes, P. J., Pedersen, S., Busse, W. W., Efficacy and safety of inhaled corticosteroids: an update (1998) Am. J. Respir. Crit. Care Med., 157, pp. S1-S53
Barnes, P. J., Therapeutic strategies for allergic diseases (1999) Nature, 402 (SUPPL), pp. B31-B38
Baylink, D. J., Glucocorticoid-induced osteoporosis (1983) N. Engl. J. Med., 309, pp. 306-308
Kinet, J. P., Blank, U., Brini, A., Jouvin, M. H., Kuster, H., Mejan, O., Ra, C., The high-affinity receptor for immunoglobulin E: a target for therapy of allergic diseases (1991) Int. Arch. Allergy Appl. Immunol., 94, pp. 51-55
Lee, E., Choi, E. J., Cheong, H., Kim, Y. -R., Ryu, S. Y., Kim, K. -M., Anti-allergic actions of the leaves of Castanea crenata and isolation of an active component responsible for the inhibition of mast cell degranulation (1999) Arch. Pharm. Res., 22, pp. 320-323
Marshall, G. D., Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents (2000) J. Allergy Clin. Immunol., 106, pp. 303-309
Meltzer, E. O., Grant, J. A., Impact of ceterizine on the burden of allergic rhinitis (1999) Ann. Allergy Asthma Immunol., 83, pp. 455-463
Michaelsen, T. E., Ihle, ., Beckstr m, K. J., Herstad, T. K., Kolberg, J., H iby, E. A., Aase, A., Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1. 7 and P1. 16 epitopes (2003) Infect. Immun., 71, pp. 5714-5723
Nakamura, G. R., Starovasnik, A., Reynolds, M. E., Lowman, H. B., A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor (2001) Biochemistry, 40, pp. 9828-9835
Nakamura, G. R., Reynolds, M. E., Chen, Y. M., Starovasnik, M. A., Lowman, H. B., Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor (2002) Proc. Natl. Acad. Sci. U. S. A., 99, pp. 1303-1308
Piper, J. M., Ray, W. A., Daugherty, J. R., Griffin, M. R., Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs (1991) Ann. Intern. Med., 114, pp. 735-740
Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., Jardieu, P. M., Humanization of an antibody direct against IgE (1993) J. Immunol., 151, pp. 2623-2632
Rigby, L. J., Trist, H., Snider, J., Hulett, M. D., Hogarth, P. M., Monoclonal antibodies and synthetic peptides define the active site of FcepsilonRI and a potential receptor antagonist (2000) Allergy, 55, pp. 609-619
Till, S. J., Francis, J. N., Nouri-Aria, K., Durham, S. R., Mechanisms of immunotherapy (2004) J. Allergy Clin. Immunol., 113, pp. 1025-1034
van der Kleij, H. P., Kraneveld, A., van Houwelingen, A. H., Kool, M., Weitemberg, A. C., Redegeld, F. A., Nijkamp, F. P., Murine model for non-IgE-mediated asthma (2004) Inflammation, 28, pp. 115-125
Wiegand, T. W., Williams, P. B., Dreskin, S. C., Jouvin, M. H., Kinet, J. P., Tasset, D., High-affinity oligonucleotide ligands to human IgE Inhibit binding to Fc Receptor I (1996) J. Immunol., 157, pp. 221-230
Yan, H., Lamm, M. E., Bj rling, E., Huang, Y. T., Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model (2002) J. Virol., 76, pp. 10972-10979
Anti-allergic properties of a new all-D synthetic immunoglobulin-binding peptide
Using a combinatorial chemistry approach, we identified a tetrameric tripeptide, denoted Protein A Mimetic (PAM) or TG19318, able to bind to immunoglobulins of different classes and species. The inverso variant, with the tripeptide in the all-D configuration (D-PAM or TG19320) is described as retaining binding properties to Ig. This peptide has now been assayed as a binder for E class immunoglobulins, in linear and competitive ELISA experiments. dot-blot and surface plasmon resonance (SPR) analyses. We show that D-PAM binds IgE with high specificity and selectivity. the interaction being sufficient to inhibit anaphylactic release of beta-hexosaminidase from RBL 2H3 cells, with an IC50 value of 10 mu g/mL. Intradermal administration of D-PAM suppresses PCA in the rat, with an IC50 of 1.25 mu g/kg dose of peptide, while its intraperitoneal injection inhibits mouse PCA with an IC50 of about 7 mg/kg and an efficacy comparable to that of ketotifen. Similarly, D-PAM inhibits ACA in the mouse, with 50% suppression at 10 mg/kg. The results presented here show that the peptide is active on the studied models, with effective doses below toxicity level, hence the molecule is a promising candidate for development of a new class of anti-allergic drugs. (C) 2007 Elsevier Ltd. All rights reserved.
Using a combinatorial chemistry approach, we identified a tetrameric tripeptide, denoted Protein A Mimetic (PAM) or TG19318, able to bind to immunoglobulins of different classes and species. The inverso variant, with the tripeptide in the all-D configuration (D-PAM or TG19320) is described as retaining binding properties to Ig. This peptide has now been assayed as a binder for E class immunoglobulins, in linear and competitive ELISA experiments. dot-blot and surface plasmon resonance (SPR) analyses. We show that D-PAM binds IgE with high specificity and selectivity. the interaction being sufficient to inhibit anaphylactic release of beta-hexosaminidase from RBL 2H3 cells, with an IC50 value of 10 mu g/mL. Intradermal administration of D-PAM suppresses PCA in the rat, with an IC50 of 1.25 mu g/kg dose of peptide, while its intraperitoneal injection inhibits mouse PCA with an IC50 of about 7 mg/kg and an efficacy comparable to that of ketotifen. Similarly, D-PAM inhibits ACA in the mouse, with 50% suppression at 10 mg/kg. The results presented here show that the peptide is active on the studied models, with effective doses below toxicity level, hence the molecule is a promising candidate for development of a new class of anti-allergic drugs. (C) 2007 Elsevier Ltd. All rights reserved.
Anti-allergic properties of a new all-D synthetic immunoglobulin-binding peptide
No results. |
431 views. Last view on Saturday 28 January 2023, 4:17:27
ibb.cnr.it
